NCT04745559 2026-01-29
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
Clinical Trials
3 trialsNCT02518555 2026-01-07
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02309515 2021-01-19
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Mayo Clinic
Phase 2 Terminated